<DOC>
	<DOCNO>NCT02225652</DOCNO>
	<brief_summary>TITLE : A Phase II Study Dose Density Regimen Fluorouracil , Epirubicin Cyclophosphamide Days 1 , 4 Every 14 Days Filgrastim Support follow Weekly Paclitaxel Women Primary Breast Cancer . PROTOCOL CODE : IRST 174.05 PHASE : II STUDY DESIGN : Pharmacological , open-label , prospective , randomize , monocentric trial DESCRIPTION OF STUDY TREATMENT : FEC + filgrastim x 3 cycle q 14-21 day Day 1 day 4 = FEC ( FLUOROURACIL 500 mg/m2 IV infusion 30 minute + EPIRUBICIN 60 mg/m2 IV infusion 1 hour + CYCLOPHOSPHAMIDE 500 mg/m2 IV infusion 30 minute ) . From day 7 hematological recovery = Filgrastim 300 microg s.c. After 21 day last FEC cycle = Paclitaxel 100 mg/m2 IV infusion 1hour ( weekly 8 cycle , day 1 ) . NUMBER OF SUBJECTS : first stage , 11 patient plan , additional 27 patient second stage least 7 patient complete plan treatment . OBJECTIVES Primary objective : trial design assess feasibility propose regimen regard toxicity deliverability . Tolerability define absence grade 3 high nonhematologic toxicity ( exclude alopecia , nausea/vomit , bone pain , might consequence administration filgrastim ) . Deliverability measure percentage patient complete plan treatment . Secondary objective : - Relapse-free survival : measure enrollment first date date document relapse ( death ) date last tumor assessment ( document relapse ) , date last tumor assessment start antitumor therapy plan protocol . - Overall survival : measure enrollment date death cause last follow-up . CORRELATIVE/SPECIAL STUDIES : evaluate retrospectively potential biomarkers activity toxicity regimen , blood plasma sample 15 mL one collect study entry , first docetaxel administration 3-4 week last docetaxel administration . Moreover , paraffin block specimen primary tumor collect biological study . STATISTICAL CONSIDERATIONS : This trial design assess feasibility propose regimen regard toxicity deliverability . Tolerability define absence grade 3 high non-hematologic toxicity ( exclude alopecia , nausea/vomit , bone pain , might consequence administration filgrastim ) . A Simon two-stage design use 60 % tolerability rate consider promising 80 % tolerability rate promising , probability type I type II error set 0.10 . In first stage , 11 patient plan , additional 27 patient second stage least 7 patient complete plan treatment . The regimen would consider tolerable worthy study end trial 27 38 patient complete plan treatment .</brief_summary>
	<brief_title>A Phase II Study Dose Density Regimen With Fluorouracil , Epirubicin Cyclophosphamide Days 1 , 4 Every 14 Days With Filgrastim Support Followed Weekly Paclitaxel Women With Primary Breast Cancer .</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Epirubicin</mesh_term>
	<mesh_term>Lenograstim</mesh_term>
	<criteria>Patients must histologically cytologically confirm primary breast cancer Age ≥18 &lt; 70 year Eastern Cooperative Oncology Group ( ECOG ) performance status ≤1 ( see appendix B ) &gt; 4 positive axillary node highrisk breast cancer &lt; 4 nodepositive node negative disease . Patients &lt; 4 nodepositive node negative disease eligible tumor &gt; 1cm two follow present : histologic grade 3 , Ki67 &gt; 30 % , estrogen receptor ( ER ) negativity , lymphovascular invasion [ 39 ] Adequate hematological , hepatic renal function , follow : hemoglobin ≥ 9 g/dl , absolute neutrophil count ≥1,500/mL , platelets ≥100,000/mL , total bilirubin ≤1.5 x ULN , alkaline phosphatase , AST ( SGOT ) ALT ( SGPT ) ≤ 2.5 x ULN ( ≤ 5 x ULN liver metastasis present ) , serum creatinine ≤ 1.5 x ULN calculate creatinine clearance &gt; 50 mL/min . Either INR APTT &lt; 1.5 x ULN ; Known hormone receptor status ( ER/PgR ER alone ) ; Must receive chemotherapy regimen . Baseline LVEF ≥55 % measure echocardiography No expression and/or amplification HER2 invasive component primary tumour ( case neoadjuvant treatment , tissue sample use HER2 test collect neoadjuvant treatment start ) Negative pregnancy test 7 day randomization ; test pregnancy omit woman without reproductive potential ( e.g . : postmenopausal woman , i.e . amenorrhoea ≥2 year previous hysterectomy bilateral ovariectomy ) . Women childbearing potential must agree use adequate contraception time randomization duration study participation . Should woman become pregnant suspect pregnant participating study , must inform treat physician coordinating centre ( CC ) immediately ; woman lactation period must exclude ; Completion necessary baseline laboratory radiological investigation Ability understand willingness sign write informed consent document . Signed write informed consent Metastatic disease Participation another clinical trial investigational agent within 30 day prior study screen . Contraindications hypersensitivity study drug ; Past ( less 10 year ) current history malignant neoplasm , except curatively treated 1 ) basal squamous cell carcinoma skin 2 ) carcinoma situ cervix . NOTE : Patients prior malignancy diagnose great 10 year past curatively treat surgery ONLY , WITHOUT radiation therapy systemic therapy ( chemotherapy endocrine ) eligible study . Patients prior diagnosis invasive breast cancer melanoma , time , exclude study . Serious cardiac illness medical condition include confine : History document congestive heart failure ( CHF ) systolic dysfunction ( LVEF &lt; 55 % ) ; Highrisk uncontrolled arrhythmia ( ventricular tachycardia , highgrade AVblock , supraventricular arrhythmia adequately ratecontrolled ) ; Angina pectoris require antianginal medication ; Clinically significant valvular heart disease ; Evidence transmural infarction ECG ; Poorly control hypertension ( e.g . systolic &gt; 180mm Hg diastolic &gt; 100mm Hg ) ; Other concurrent serious disease may interfere plan treatment include severe pulmonary conditions/illness ; Any follow abnormal laboratory test immediately prior randomisation : serum total bilirubin &gt; 1.5 x upper limit normal ( ULN ) . In case know Gilbert 's syndrome , high serum total bilirubin ( &lt; 2 x ULN ) allow alanine amino transferase ( ALAT ) aspartate amino transferase ( ASAT ) &gt; 2.5 x ULN ; alkaline phosphatase ( ALP ) &gt; 2.5 x ULN ; serum creatinine &gt; 2.0 x ULN ; total white blood cell count ( WBC ) &lt; 2.5 x 109/L ; absolute neutrophil count &lt; 1.5 x 109/L ; platelet &lt; 100 x 109/L . Malabsorption syndrome , disease significantly affect gastrointestinal function , resection stomach small bowel , person unable swallow oral medication . Subjects ulcerative colitis also exclude ; Pregnant , lactate woman childbearing potential without negative pregnancy test urine serum , within 7 day prior randomization , irrespective method contraception use , include tubal ligation . Women childbearing potential , include woman whose last menstrual period &lt; 12 month ago ( unless surgically sterile ) unable unwilling use adequate contraceptive measure study treatment . ( adequate contraceptive measure intrauterine device , barrier method condom , diaphragm also conjunction spermicidal jelly , total abstinence . Oral , injectable implant hormonal contraceptive allow study )</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>August 2014</verification_date>
</DOC>